Shares of Revolution Medicines Inc. /zigman2/quotes/216320743/composite RVMD +14.59% , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a revised range. The Redwood City, California-based company sold 14 million shares priced at $17 each to raise $238 million. The deal was upsized from an earlier plan to offer 10 million shares priced at $14 to $16 each. JPMorgan, Cowen, SVB Leerink and Guggenheim were underwriters on the deal. Proceeds will be used to fund R&D, to move toward clinical trials for some candidates and for general corporate purposes. "We are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways," says the prospectus.